Studies tissue samples to predict response in early lung cancer
Studies tissue samples from people with early-stage lung cancer who had chemotherapy.
Plain-language title generated from the registry record
Registry title: Biomarkers in Predicting Treatment Response in Samples From Patients With Early-Stage Non-Small Cell Lung Cancer Previously Treated With Adjuvant Chemotherapy
Key facts
- Where
- Kingston, CanadaSee the site
Where in Canada
- National Cancer Institute of Canada Clinical Trials GroupKingston, CanadaNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- National Cancer Institute (NCI)
- Trial code
- NCT01595074
- Record updated
- 20 September 2013
- Original description
This research trial studies biomarkers in predicting treatment response in samples from patients with early-stage non-small cell lung cancer previously treated with adjuvant chemotherapy. Studying samples of tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer. It may also help doctors predict how patients will respond to treatment.Read full original descriptionShow less
The Identification, Validation and Implemention of Prognostic and/or Predictive Biomarkers for Adjuvant Chemotherapy in Early Stage Non-Small Cell Lung Cancer (NSCLC)
This research trial studies biomarkers in predicting treatment response in samples from patients with early-stage non-small cell lung cancer previously treated with adjuvant chemotherapy. Studying samples of tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer. It may also help doctors predict how patients will respond to treatment.
Inclusion: Samples from patients treated in 4 adjuvant chemotherapy (ACT) for early-stage non-small cell lung cancer (NSCLC) pivotal trials:; International Adjuvant Lung Cancer Trail (IALT); Cancer and Leukemia Group B (CALGB)-9633; CAN-NCIC-BR10; Adjuvant Navelbine International Trialist Association (ANITA); Not specified; See Disease Characteristics.